Monkeypox Testing Market Size, Share, Growth, Industry Analysis, Trends and Dynamics, By Types (Polymerase Chain Reaction (PCR), Lateral Flow Assay (LFA), Others), By Applications (Hospitals & Clinics, Diagnostic Laboratories, Others) , and Regional Insights and Forecast to 2035

Monkeypox Testing Market Size

Global Monkeypox Testing Market size was USD 1.44 billion in 2025 and is projected to touch USD 1.51 billion in 2026, USD 1.57 billion in 2027 to USD 2.22 billion by 2035, exhibiting a CAGR of 4.41% during the forecast period (2026-2035).

The Global Monkeypox Testing Market is expanding steadily as healthcare systems continue improving infectious disease detection and laboratory preparedness. Rising awareness of viral disease surveillance, increasing molecular diagnostic adoption, and stronger public health monitoring are supporting market expansion. More than 81% of reference laboratories now use molecular testing methods for accurate diagnosis, while nearly 73% of healthcare facilities have strengthened outbreak response programmes. Around 67% of laboratories continue improving automation, and approximately 59% of healthcare organisations are investing in advanced laboratory reporting systems to improve diagnostic efficiency and patient management.

The US Monkeypox Testing Market continues to benefit from advanced healthcare infrastructure and strong infectious disease surveillance programmes. Nearly 84% of public health laboratories use molecular diagnostic technologies for confirmatory testing, while around 76% of hospitals maintain emergency outbreak response protocols. Approximately 69% of diagnostic laboratories have automated testing workflows, improving operational efficiency and reducing reporting time. Continuous laboratory investment, better disease monitoring, and growing collaboration between healthcare providers and public health agencies continue supporting market growth across the United States.

The Japan Monkeypox Testing Market is growing steadily with increasing focus on laboratory quality, disease surveillance, and advanced diagnostic technologies. Nearly 71% of specialised laboratories have strengthened molecular diagnostic capabilities, while approximately 63% of healthcare facilities continue expanding infectious disease preparedness programmes. Around 56% of hospitals have improved laboratory automation and digital reporting systems to support faster diagnosis. Continued investment in laboratory infrastructure, skilled healthcare professionals, and strong regulatory standards is helping improve testing efficiency and public health response throughout Japan.

Key Findings

• Market Size: Global Monkeypox Testing Market reached USD 1.44 billion in 2025, USD 1.51 billion in 2026, and is projected to reach USD 2.22 billion by 2035 at a CAGR of 4.41%.
• Growth Drivers: More than 81% of laboratories use molecular diagnostics, 73% strengthened surveillance systems, 67% improved laboratory automation, and 59% expanded outbreak preparedness.
• Trends: Around 78% adopted PCR platforms, 64% expanded automation, 58% integrated digital reporting, and 52% increased multiplex diagnostic testing capabilities.
• Top Key Players: Thermo Fisher Scientific, QIAGEN, Quest Diagnostics, Inc., Laboratory Corp. of America Holdings, BD, and more.
• Regional Insights: North America holds 38%, Europe 29%, Asia-Pacific 24%, and Middle East & Africa 9%, supported by expanding laboratory infrastructure and infectious disease preparedness.
• Challenges: Nearly 42% report workforce shortages, 39% face laboratory access limitations, 35% experience supply disruptions, and 31% encounter delayed diagnostic reporting.
• Industry Impact: Around 74% improved laboratory readiness, 66% strengthened surveillance, 58% expanded automation, and 53% enhanced diagnostic workflow efficiency.
• Recent Developments: Nearly 61% focused on assay improvements, 54% expanded automation, 47% upgraded reporting systems, and 41% enhanced laboratory integration.

The Monkeypox Testing Market has become an important part of infectious disease preparedness because laboratories now focus on rapid identification, accurate diagnosis, and faster public health response. The market is witnessing higher adoption of automated molecular testing systems, improved laboratory networking, and better digital reporting. Many healthcare organisations are expanding emergency diagnostic capabilities to improve outbreak management. Continuous improvements in PCR technology, laboratory quality standards, biosafety practices, and workforce training are helping diagnostic providers deliver reliable testing services while strengthening disease surveillance and healthcare readiness across different regions.

Monkeypox Testing Market Trends

The Monkeypox Testing Market is growing due to rising awareness of infectious disease surveillance, stronger laboratory networks, and improved molecular diagnostic technologies. Healthcare providers are expanding testing capacity to identify suspected cases faster and reduce disease transmission. More than 85% of reference laboratories now rely on molecular diagnostic methods for orthopoxvirus detection because of their high accuracy. Around 72% of healthcare institutions have improved sample handling and biosafety procedures to support infectious disease testing. Nearly 68% of public health laboratories have strengthened emergency testing protocols, while over 60% of hospitals continue investing in rapid diagnostic preparedness. The Monkeypox Testing Market also benefits from better collaboration between hospitals, diagnostic laboratories, and government health agencies.

Technology improvements remain one of the strongest trends shaping the Monkeypox Testing Market. Approximately 78% of advanced laboratories now use real-time PCR platforms for confirmatory diagnosis because of their sensitivity and specificity. Nearly 64% of diagnostic facilities have integrated automated sample preparation systems, reducing manual errors and improving workflow efficiency. Around 58% of laboratories have adopted multiplex testing approaches that identify multiple viral pathogens from a single sample. More than 55% of healthcare providers have expanded digital laboratory reporting systems, enabling quicker communication between testing centres and public health authorities.

Monkeypox Testing Market Dynamics

OPPORTUNITY

Expansion of Public Health Surveillance and Rapid Diagnostic Networks

The Monkeypox Testing Market has strong opportunities as countries continue strengthening infectious disease monitoring systems. More than 74% of public health agencies are increasing laboratory preparedness for emerging viral outbreaks. Around 66% of regional laboratories are expanding molecular diagnostic capabilities, while nearly 61% of healthcare facilities are investing in faster sample processing technologies. Over 57% of diagnostic centres are improving digital reporting systems to support real-time disease surveillance. Approximately 53% of hospitals are increasing collaborations with reference laboratories to improve testing coverage. These improvements are creating long-term demand for rapid, reliable, and accurate monkeypox testing solutions across healthcare systems worldwide.

DRIVERS

Growing Need for Early Detection of Infectious Diseases

Increasing demand for early diagnosis remains one of the biggest growth drivers for the Monkeypox Testing Market. Nearly 82% of confirmed infections require laboratory verification using molecular diagnostic methods. Around 69% of healthcare providers prioritise rapid testing to reduce transmission risks and improve patient isolation. More than 63% of hospitals have expanded infectious disease laboratory services, while approximately 58% of diagnostic laboratories have upgraded PCR equipment for higher testing capacity. About 55% of healthcare authorities continue improving outbreak preparedness programmes, encouraging broader adoption of advanced monkeypox testing technologies across hospitals, laboratories, and public health institutions.

RESTRAINTS

"Limited laboratory infrastructure in developing healthcare systems"

The Monkeypox Testing Market continues to face restraints because diagnostic infrastructure remains uneven across several developing regions. Nearly 48% of smaller healthcare facilities have limited access to advanced molecular diagnostic equipment. Around 44% of laboratories experience shortages of trained laboratory professionals, while approximately 39% report delays in obtaining specialised testing materials. More than 36% of rural healthcare centres depend on external laboratories for confirmatory testing, increasing turnaround times. About 33% of healthcare institutions also report limited biosafety facilities for handling infectious samples. These infrastructure gaps reduce testing accessibility and slow disease surveillance efforts in several regions.

CHALLENGE

"Maintaining testing readiness during fluctuating outbreak levels"

The Monkeypox Testing Market faces challenges in maintaining laboratory readiness when disease activity changes significantly. Around 59% of laboratories experience fluctuating testing demand during outbreak periods. Nearly 52% of healthcare facilities report difficulty balancing routine diagnostic services with emergency infectious disease testing. Approximately 46% of laboratories face challenges in maintaining sufficient testing supplies during sudden increases in sample volume. More than 41% of healthcare organisations highlight the need for continuous workforce training, while about 38% identify inventory management as a major operational issue. Maintaining consistent preparedness without unnecessary resource use remains an ongoing challenge for healthcare systems.

Segmentation Analysis

The Monkeypox Testing Market is segmented by type and application based on diagnostic technology and end-user demand. Global Monkeypox Testing Market size was USD 1.44 Billion in 2025 and is projected to touch USD 1.51 Billion in 2026 to USD 2.22 Billion by 2035, exhibiting a CAGR of 4.41% during the forecast period. Polymerase Chain Reaction (PCR) remains the preferred testing method because of its high sensitivity and reliable confirmation of infection, while Lateral Flow Assay (LFA) is gaining attention for rapid screening and point-of-care use. Hospitals, diagnostic laboratories, and other healthcare facilities continue expanding testing capacity through better laboratory infrastructure, trained professionals, and improved disease surveillance. The growing focus on fast diagnosis, outbreak monitoring, and public health preparedness supports steady demand across every segment of the Monkeypox Testing Market.

By Type

Polymerase Chain Reaction (PCR)

Polymerase Chain Reaction (PCR) is the leading diagnostic method in the Monkeypox Testing Market because it provides highly accurate confirmation of viral infection. More than 80% of reference laboratories use PCR for confirmatory testing, while nearly 70% of public health laboratories rely on this technology during outbreak investigations. Around 65% of healthcare providers prefer PCR because it delivers reliable results and supports effective patient management. Continuous laboratory upgrades and better molecular testing capacity continue supporting this segment.

Polymerase Chain Reaction (PCR) held the largest share in the Monkeypox Testing Market, accounting for USD 0.89 Billion in 2025, representing 61.8% of the total market. This segment is expected to grow at a CAGR of 4.90% from 2025 to 2035, supported by high diagnostic accuracy, strong laboratory adoption, and increasing infectious disease surveillance.

Lateral Flow Assay (LFA)

Lateral Flow Assay (LFA) is becoming an important testing option because it provides quick screening with simple operation. Nearly 58% of healthcare workers prefer rapid testing methods during initial patient assessment, while about 45% of community health programmes use rapid diagnostic kits for faster screening. Around 40% of emergency healthcare facilities are expanding point-of-care testing capabilities to improve response time and reduce pressure on central laboratories.

Lateral Flow Assay (LFA) accounted for USD 0.36 Billion in 2025, representing 25.0% of the total Monkeypox Testing Market. This segment is projected to expand at a CAGR of 4.20% from 2025 to 2035, supported by growing demand for rapid diagnosis, easy operation, and wider use in decentralized healthcare settings.

Others

The others segment includes viral culture, sequencing methods, immunological testing, and supporting laboratory techniques. These methods are mainly used for research activities, epidemiological studies, and additional clinical confirmation. Nearly 30% of specialised laboratories use complementary diagnostic approaches alongside PCR, while about 24% of research institutions continue evaluating advanced testing technologies for future infectious disease management and surveillance programmes.

Others accounted for USD 0.19 Billion in 2025, representing 13.2% of the Monkeypox Testing Market. This segment is anticipated to grow at a CAGR of 3.60% from 2025 to 2035 due to continued research activities, specialised diagnostic requirements, and laboratory innovation.

By Application

Hospitals & Clinics

Hospitals and clinics remain major users of monkeypox testing because they manage suspected patients, emergency diagnosis, and infection control. Around 72% of suspected cases are initially evaluated in hospitals, while nearly 60% of healthcare facilities have strengthened isolation and diagnostic protocols. Improved laboratory access, better patient monitoring, and stronger public health coordination continue increasing testing demand across hospitals and clinics.

Hospitals & Clinics accounted for USD 0.58 Billion in 2025, representing 40.0% of the Monkeypox Testing Market. This application is expected to grow at a CAGR of 4.20% from 2025 to 2035, supported by higher patient admissions, better laboratory integration, and improved infectious disease preparedness.

Diagnostic Laboratories

Diagnostic laboratories play a central role by providing confirmatory testing and high-volume sample processing. More than 68% of confirmed samples are processed through specialised laboratories, while approximately 63% of molecular testing centres continue expanding PCR capacity. Better automation, skilled laboratory staff, and faster reporting systems help diagnostic laboratories maintain consistent testing quality and improve outbreak response.

Diagnostic Laboratories accounted for USD 0.65 Billion in 2025, representing 45.0% of the Monkeypox Testing Market. This application is projected to grow at a CAGR of 4.80% from 2025 to 2035 due to increasing laboratory capacity, molecular testing demand, and public health surveillance programmes.

Others

The others segment includes research institutes, academic laboratories, government testing centres, and mobile healthcare units. These facilities support disease surveillance, scientific studies, and emergency testing during public health events. Nearly 28% of surveillance programmes involve research laboratories, while around 22% of government facilities continue expanding outbreak monitoring and laboratory preparedness activities.

Others accounted for USD 0.21 Billion in 2025, representing 15.0% of the Monkeypox Testing Market. This application is expected to expand at a CAGR of 3.50% from 2025 to 2035, supported by research activities, public health programmes, and specialised laboratory services.

Monkeypox Testing Market Regional Outlook

The Global Monkeypox Testing Market was valued at USD 1.44 Billion in 2025 and is projected to reach USD 1.51 Billion in 2026 before expanding to USD 2.22 Billion by 2035, registering a CAGR of 4.41% during the forecast period. Regional demand is supported by stronger laboratory infrastructure, infectious disease surveillance, and public health preparedness. North America accounts for 38% of the market, Europe holds 29%, Asia-Pacific contributes 24%, and Middle East & Africa represents 9%. Continued investment in molecular diagnostics, laboratory expansion, and emergency response systems supports steady growth across all regional markets.

North America

North America continues to maintain strong demand for monkeypox testing because of advanced healthcare systems, widespread molecular diagnostic facilities, and active disease surveillance programmes. More than 82% of reference laboratories use PCR-based testing, while approximately 75% of hospitals maintain infectious disease preparedness protocols. Around 68% of diagnostic centres have automated laboratory workflows, improving testing speed and reporting efficiency. Public awareness campaigns and better laboratory coordination continue supporting routine testing and outbreak response across healthcare facilities.

North America represents approximately USD 0.57 Billion, accounting for nearly 38% of the market in 2026. Strong healthcare infrastructure and advanced laboratory capabilities continue supporting regional demand.

Regulatory support is provided by agencies such as the U.S. Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and Health Canada, which guide laboratory quality, testing standards, emergency response, and public health surveillance.

Europe

Europe continues expanding monkeypox testing through coordinated public health programmes and modern laboratory networks. Nearly 74% of public laboratories have strengthened molecular testing capacity, while about 66% of hospitals maintain infectious disease response plans. Around 60% of diagnostic laboratories have improved digital reporting systems to support rapid communication with health authorities. Growing collaboration between healthcare providers and research institutions continues improving disease monitoring and laboratory preparedness throughout the region.

Europe accounts for approximately USD 0.44 Billion, representing nearly 29% of the market in 2026.

Regional oversight is supported by the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC), and national public health authorities, which promote laboratory quality standards and coordinated disease surveillance.

Asia-Pacific

Asia-Pacific is steadily improving monkeypox testing through expanded healthcare infrastructure and growing laboratory investments. More than 62% of urban diagnostic centres now provide molecular diagnostic services, while nearly 54% of healthcare organisations continue strengthening infectious disease monitoring. Around 49% of laboratories are introducing automated testing systems to improve efficiency. Better training programmes and stronger government support continue increasing access to reliable diagnostic services across the region.

Asia-Pacific represents approximately USD 0.36 Billion, accounting for nearly 24% of the market in 2026.

Regulatory guidance is supported by organisations including Japan's PMDA, China's National Medical Products Administration (NMPA), India's Central Drugs Standard Control Organization (CDSCO), and other national health authorities responsible for diagnostic quality and laboratory compliance.

Middle East & Africa

Middle East & Africa continues improving monkeypox testing through expanding laboratory capacity and better public health planning. Nearly 46% of healthcare facilities are strengthening infectious disease surveillance, while about 40% of laboratories are increasing molecular testing capabilities. Around 35% of public hospitals continue improving laboratory equipment and workforce training. Better regional cooperation, improved emergency preparedness, and stronger disease monitoring programmes are helping increase testing accessibility across several countries.

Middle East & Africa accounts for approximately USD 0.14 Billion, representing nearly 9% of the market in 2026.

Regulatory support comes from national ministries of health, regional public health agencies, and collaboration with the World Health Organization Regional Offices, helping strengthen laboratory quality, disease reporting, and emergency outbreak management across the region.

List of Key Monkeypox Testing Market Companies Profiled

Investment Analysis and Opportunities in Monkeypox Testing Market

The Monkeypox Testing Market continues to attract investment because healthcare systems are strengthening infectious disease preparedness and laboratory capabilities. Nearly 74% of healthcare organisations are increasing investments in molecular diagnostic technologies to improve testing accuracy. Around 69% of public health laboratories are expanding PCR capacity, while about 63% of diagnostic centres are introducing automated sample preparation systems. Nearly 58% of healthcare providers are improving laboratory information systems for faster reporting and better case management.

New investment opportunities are emerging through rapid diagnostic technologies, portable testing platforms, multiplex assays, and digital laboratory solutions. Around 61% of diagnostic companies are focusing on research and development for next-generation molecular testing products. Nearly 55% of laboratory networks are expanding regional testing facilities, while approximately 49% of healthcare organisations are improving emergency stock management for infectious disease diagnostics. Close to 46% of healthcare programmes are promoting collaboration between government laboratories and private diagnostic companies.

New Products Development

Manufacturers are introducing advanced diagnostic products that improve testing accuracy, turnaround time, and laboratory efficiency. Nearly 72% of newly introduced testing solutions focus on real-time PCR technology with higher sensitivity. Around 64% of product development activities involve simplified sample preparation methods that reduce laboratory workload. About 57% of companies are integrating automated processing features to minimise manual handling, while nearly 51% are improving reagent stability for better storage and transportation. These innovations support faster diagnosis and stronger outbreak management.

Product development also focuses on portable testing systems, multiplex diagnostic kits, and digital reporting integration. Nearly 54% of manufacturers are developing compact diagnostic platforms suitable for regional laboratories and mobile healthcare units. Around 47% of new diagnostic solutions include software integration for faster reporting and surveillance. Approximately 43% of research programmes are evaluating broader orthopoxvirus detection capabilities to improve laboratory preparedness. Continuous innovation is helping healthcare providers improve diagnostic quality while increasing testing accessibility across different healthcare environments.

Developments

• Thermo Fisher Scientific: Expanded its molecular diagnostic workflow for orthopoxvirus detection by improving assay efficiency and laboratory compatibility. Internal laboratory evaluations reported more than 96% analytical agreement, helping diagnostic laboratories improve workflow consistency and testing confidence during infectious disease surveillance programmes.
• QIAGEN: Strengthened its sample preparation and PCR workflow solutions for infectious disease laboratories. Updated automation features reduced manual processing steps by approximately 30%, improving laboratory productivity and supporting higher daily sample processing capacity across healthcare facilities.
• BD: Enhanced laboratory specimen collection products designed for infectious disease testing. Improved sample stability supported accurate transportation, while laboratory users reported nearly 25% better handling efficiency during routine diagnostic operations and emergency response activities.
• Quest Diagnostics, Inc.: Expanded laboratory testing availability through a wider diagnostic network, improving turnaround efficiency and increasing access for healthcare providers. Laboratory optimisation programmes improved operational performance by nearly 22%, supporting faster reporting and stronger disease surveillance activities.
• Laboratory Corp. of America Holdings: Increased infectious disease laboratory preparedness by expanding molecular testing capacity and improving digital reporting systems. Workflow improvements reduced reporting delays by approximately 20%, allowing healthcare professionals to receive diagnostic information more efficiently.

Report Coverage

This report provides detailed analysis of the Monkeypox Testing Market by examining market trends, competitive landscape, technology developments, segmentation, regional performance, and future business opportunities. It evaluates Polymerase Chain Reaction (PCR), Lateral Flow Assay (LFA), and other testing technologies along with application analysis covering hospitals and clinics, diagnostic laboratories, and other healthcare facilities. The report also reviews demand patterns, laboratory expansion, public health preparedness, and emerging diagnostic technologies influencing market development.

The study includes a concise SWOT analysis to support strategic business planning. Strengths include high diagnostic accuracy, expanding molecular testing infrastructure, and growing laboratory automation, with more than 80% of reference laboratories relying on molecular diagnostic methods. Weaknesses include limited laboratory infrastructure in certain regions, affecting nearly 40% of smaller healthcare facilities. Opportunities arise from expanding public health surveillance, where approximately 70% of healthcare systems continue improving outbreak preparedness.

Future Scope

The future of the Monkeypox Testing Market remains positive as governments, healthcare providers, and diagnostic companies continue strengthening infectious disease preparedness. Nearly 78% of healthcare organisations are expected to increase investment in molecular diagnostics, while approximately 68% of laboratories are planning further automation of sample processing and reporting systems. Around 63% of diagnostic centres are expected to expand multiplex testing capabilities that allow multiple viral pathogens to be identified from a single patient sample. These improvements will support faster diagnosis, better patient care, and stronger outbreak response.

Future market development will also be supported by wider use of digital laboratory management systems, portable diagnostic devices, and artificial intelligence-assisted reporting tools. Nearly 59% of diagnostic manufacturers are focusing on smart laboratory technologies, while approximately 53% are developing next-generation rapid testing solutions suitable for decentralised healthcare facilities. Around 48% of healthcare providers are expected to strengthen collaboration with research institutions to improve infectious disease surveillance. Better laboratory connectivity, improved biosafety standards, enhanced workforce training, and wider access to molecular diagnostics will continue improving testing quality.